NCT01193478View on ClinicalTrials.gov

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

PHASE1CompletedINTERVENTIONAL

Enrollment

71

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

December 31, 2011

Conditions

HCV Infection

Interventions

DRUG

GS-5885

tablet, oral, 3 mg once daily for 3 days

DRUG

Placebo

tablet, oral, once daily for 3 days

DRUG

GS-5885

tablet, oral, 10 mg once daily for 3 days

DRUG

Placebo

tablet, oral, once daily for 3 days

DRUG

GS-5885

tablet, oral, 30 mg once daily for 3 days

DRUG

Placebo

tablet, oral, once daily for 3 days

DRUG

GS-5885

tablet, oral, up to 90 mg once daily for 3 days

DRUG

Placebo

tablet, oral, once daily for 3 days

DRUG

GS-5885

tablet, oral, up to 90 mg once daily for 3 days

DRUG

Placebo

tablet, oral, once daily for 3 days

DRUG

GS-5885

tablet, oral, up to 90 mg once daily for 3 days

DRUG

Placebo

tablet, oral, once daily for 3 days

Trial Locations (13)

19139

Philadelphia

20010

Washington D.C.

32720

DeLand

32809

Orlando

33169

Miami

63104

St Louis

77030

Houston

78215

San Antonio

90630

Cypress

91950

National City

92801

Anaheim

97239

Portland

98418

Tacoma

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY